Novavax, Inc.
$11.23
▲ $0.41 (3.74%)
Day Range
$10.55 – $11.30
52W Range
$6.20 – $13.39
Volume
2,818,986
Avg Volume
5,915,346
Fundamentals are weak on several fronts. Any investment case here likely rests on a turnaround or growth story, not current business quality.
No ROE data available.
Operating margin of -89.6% suggests a thin-margin, competitive business.
Gross margin of -2.6% suggests limited pricing power or a commodity-like product.
SMA 20
$11.42
SMA 50
$10.14
SMA 200
$9.20
Ann. Volatility
111.7%
50/200-day trend
50-day average is above the 200-day average — the intermediate trend has been improving.
RSI (14)
Momentum is in a balanced range, neither overbought nor oversold.
MACD
MACD line is below its signal line, consistent with negative short-term momentum.
Bollinger Bands (20,2)
Price is trading within its normal recent volatility range.
Market Cap
$1.85B
Trailing P/E
—
Forward P/E
-68.5
PEG Ratio
1.32
Price / Book
—
Return on Equity
—
Return on Assets
-6.5%
Debt / Equity
—
Current Ratio
2.33x
Gross Margin
-2.6%
Operating Margin
-89.6%
Net Margin
-59.9%
Revenue Growth (YoY)
-76.3%
Earnings Growth (YoY)
—
Dividend Yield
0.00%
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
No debt/equity data.
Current ratio of 2.33x means short-term obligations are well covered.
Quick ratio of 2.23x shows solid liquidity without relying on inventory.
Revenue is shrinking 76.3% YoY — a red flag worth investigating.
No earnings growth data.
No trailing P/E (often means negative earnings).
PEG of 1.32 suggests growth may be more than priced in.
No price/book data.
Free cash flow is only -62% of reported net income — earnings quality worth a closer look.
Payout ratio of 0% leaves ample room to reinvest and cushion downturns.
52-week range position
Current price sits at 76% of its trailing 52-week high/low range.
Technical readings describe recent price behavior. They are not forecasts — momentum can reverse without warning.
Payout Ratio
0.0%
Beta
2.44
EPS (TTM)
-$1.58
Analyst Target (Mean)
$14.22
9 analysts
52W Range
$6.20 – $13.39